Both of these patients had KRAS testing as part of screening for potential inclusion in a trial of anti- Epidermal growth factor receptor (EGFR) monoclonal antibody, panitumumab, in KRAS wild-type pancreatic cancer (11). This evidence concerns the gene EGFR and familial pancreatic carcinoma.